Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung

A retrospective immunohistochemical study

H. Battifora, H. R. Sorensen, P. Mehta, C. Ahn, J. Niland, E. Hage, D. E. Pettijohn, L. Olsson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background. Squamous cell lung carcinoma (SLC), the most frequent type of lung cancer, generally is treated surgically and its prognosis is poor. The only current clinically useful prognostic criterion is lymph node staging (TNM classification). Expression of a novel tumor-associated carbohydrate epitope Galβ1-3[Fucα1-4]GlcNAcβ1-4[Fucα1-3]GlcNAcβ1-3Galβ1-4Glc identified by the 43-9F monoclonal antibody (MoAb) is associated with the growth pattern of SLC cell lines in athymic mice and in vitro. This implies that the 43-9F epitope may be related to tumor progression in patients with SLC and that, as such, it could be of prognostic value. Methods. Primary tumor specimens from 231 patients with lung carcinoma (130 with SLC, 64 with adenocarcinoma, 10 with small cell carcinoma, 16 with large cell carcinoma, and 11 with adenosquamous carcinoma) were examined by immunohistochemical studies on formalin-fixed, paraffin-embedded tissue samples for immunoreactivity with an MoAb to the 43-9F antigen. Univariate and step-wise Cox regression analyses were used to compare survival time by histopathologic diagnosis, smoker status, TNM classification, and type of surgical treatment. Results and Conclusions. Patients with 43-9F epitope-positive SLC tumors had a significantly (P < 0.01) better prognosis than patients with epitope- negative tumors. In contrast, no association was seen between 43-9F epitope expression and survival time for patients with lung adenocarcinomas. Further, the prognostic value of 43-9F expression in SLC was found to be superior to the N-classification with the added advantage that it requires access only to primary tumor tissue and thus is available before therapy.

Original languageEnglish (US)
Pages (from-to)1867-1872
Number of pages6
JournalCancer
Volume70
Issue number7
StatePublished - 1992

Fingerprint

Squamous Cell Carcinoma
Retrospective Studies
Lung
Epitopes
Neoplasms
Neoplasm Staging
Monoclonal Antibodies
Adenosquamous Carcinoma
Large Cell Carcinoma
Small Cell Carcinoma
Survival
tumor-associated antigen 43-9F
Nude Mice
Paraffin
Formaldehyde
Lung Neoplasms
Adenocarcinoma
Lymph Nodes
Regression Analysis
Carbohydrates

Keywords

  • 43-9F
  • immunohistochemistry
  • lung cancer
  • prognosis
  • squamous cell
  • tumor- associated antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Battifora, H., Sorensen, H. R., Mehta, P., Ahn, C., Niland, J., Hage, E., ... Olsson, L. (1992). Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung: A retrospective immunohistochemical study. Cancer, 70(7), 1867-1872.

Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung : A retrospective immunohistochemical study. / Battifora, H.; Sorensen, H. R.; Mehta, P.; Ahn, C.; Niland, J.; Hage, E.; Pettijohn, D. E.; Olsson, L.

In: Cancer, Vol. 70, No. 7, 1992, p. 1867-1872.

Research output: Contribution to journalArticle

Battifora, H, Sorensen, HR, Mehta, P, Ahn, C, Niland, J, Hage, E, Pettijohn, DE & Olsson, L 1992, 'Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung: A retrospective immunohistochemical study', Cancer, vol. 70, no. 7, pp. 1867-1872.
Battifora, H. ; Sorensen, H. R. ; Mehta, P. ; Ahn, C. ; Niland, J. ; Hage, E. ; Pettijohn, D. E. ; Olsson, L. / Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung : A retrospective immunohistochemical study. In: Cancer. 1992 ; Vol. 70, No. 7. pp. 1867-1872.
@article{eeed478808d847fa9f03a778ec52e5f7,
title = "Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung: A retrospective immunohistochemical study",
abstract = "Background. Squamous cell lung carcinoma (SLC), the most frequent type of lung cancer, generally is treated surgically and its prognosis is poor. The only current clinically useful prognostic criterion is lymph node staging (TNM classification). Expression of a novel tumor-associated carbohydrate epitope Galβ1-3[Fucα1-4]GlcNAcβ1-4[Fucα1-3]GlcNAcβ1-3Galβ1-4Glc identified by the 43-9F monoclonal antibody (MoAb) is associated with the growth pattern of SLC cell lines in athymic mice and in vitro. This implies that the 43-9F epitope may be related to tumor progression in patients with SLC and that, as such, it could be of prognostic value. Methods. Primary tumor specimens from 231 patients with lung carcinoma (130 with SLC, 64 with adenocarcinoma, 10 with small cell carcinoma, 16 with large cell carcinoma, and 11 with adenosquamous carcinoma) were examined by immunohistochemical studies on formalin-fixed, paraffin-embedded tissue samples for immunoreactivity with an MoAb to the 43-9F antigen. Univariate and step-wise Cox regression analyses were used to compare survival time by histopathologic diagnosis, smoker status, TNM classification, and type of surgical treatment. Results and Conclusions. Patients with 43-9F epitope-positive SLC tumors had a significantly (P < 0.01) better prognosis than patients with epitope- negative tumors. In contrast, no association was seen between 43-9F epitope expression and survival time for patients with lung adenocarcinomas. Further, the prognostic value of 43-9F expression in SLC was found to be superior to the N-classification with the added advantage that it requires access only to primary tumor tissue and thus is available before therapy.",
keywords = "43-9F, immunohistochemistry, lung cancer, prognosis, squamous cell, tumor- associated antigen",
author = "H. Battifora and Sorensen, {H. R.} and P. Mehta and C. Ahn and J. Niland and E. Hage and Pettijohn, {D. E.} and L. Olsson",
year = "1992",
language = "English (US)",
volume = "70",
pages = "1867--1872",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Tumor-associated antigen 43-9F is of prognostic value in squamous cell carcinoma of the lung

T2 - A retrospective immunohistochemical study

AU - Battifora, H.

AU - Sorensen, H. R.

AU - Mehta, P.

AU - Ahn, C.

AU - Niland, J.

AU - Hage, E.

AU - Pettijohn, D. E.

AU - Olsson, L.

PY - 1992

Y1 - 1992

N2 - Background. Squamous cell lung carcinoma (SLC), the most frequent type of lung cancer, generally is treated surgically and its prognosis is poor. The only current clinically useful prognostic criterion is lymph node staging (TNM classification). Expression of a novel tumor-associated carbohydrate epitope Galβ1-3[Fucα1-4]GlcNAcβ1-4[Fucα1-3]GlcNAcβ1-3Galβ1-4Glc identified by the 43-9F monoclonal antibody (MoAb) is associated with the growth pattern of SLC cell lines in athymic mice and in vitro. This implies that the 43-9F epitope may be related to tumor progression in patients with SLC and that, as such, it could be of prognostic value. Methods. Primary tumor specimens from 231 patients with lung carcinoma (130 with SLC, 64 with adenocarcinoma, 10 with small cell carcinoma, 16 with large cell carcinoma, and 11 with adenosquamous carcinoma) were examined by immunohistochemical studies on formalin-fixed, paraffin-embedded tissue samples for immunoreactivity with an MoAb to the 43-9F antigen. Univariate and step-wise Cox regression analyses were used to compare survival time by histopathologic diagnosis, smoker status, TNM classification, and type of surgical treatment. Results and Conclusions. Patients with 43-9F epitope-positive SLC tumors had a significantly (P < 0.01) better prognosis than patients with epitope- negative tumors. In contrast, no association was seen between 43-9F epitope expression and survival time for patients with lung adenocarcinomas. Further, the prognostic value of 43-9F expression in SLC was found to be superior to the N-classification with the added advantage that it requires access only to primary tumor tissue and thus is available before therapy.

AB - Background. Squamous cell lung carcinoma (SLC), the most frequent type of lung cancer, generally is treated surgically and its prognosis is poor. The only current clinically useful prognostic criterion is lymph node staging (TNM classification). Expression of a novel tumor-associated carbohydrate epitope Galβ1-3[Fucα1-4]GlcNAcβ1-4[Fucα1-3]GlcNAcβ1-3Galβ1-4Glc identified by the 43-9F monoclonal antibody (MoAb) is associated with the growth pattern of SLC cell lines in athymic mice and in vitro. This implies that the 43-9F epitope may be related to tumor progression in patients with SLC and that, as such, it could be of prognostic value. Methods. Primary tumor specimens from 231 patients with lung carcinoma (130 with SLC, 64 with adenocarcinoma, 10 with small cell carcinoma, 16 with large cell carcinoma, and 11 with adenosquamous carcinoma) were examined by immunohistochemical studies on formalin-fixed, paraffin-embedded tissue samples for immunoreactivity with an MoAb to the 43-9F antigen. Univariate and step-wise Cox regression analyses were used to compare survival time by histopathologic diagnosis, smoker status, TNM classification, and type of surgical treatment. Results and Conclusions. Patients with 43-9F epitope-positive SLC tumors had a significantly (P < 0.01) better prognosis than patients with epitope- negative tumors. In contrast, no association was seen between 43-9F epitope expression and survival time for patients with lung adenocarcinomas. Further, the prognostic value of 43-9F expression in SLC was found to be superior to the N-classification with the added advantage that it requires access only to primary tumor tissue and thus is available before therapy.

KW - 43-9F

KW - immunohistochemistry

KW - lung cancer

KW - prognosis

KW - squamous cell

KW - tumor- associated antigen

UR - http://www.scopus.com/inward/record.url?scp=0026742990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026742990&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 1867

EP - 1872

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -